Quantum BioPharma's 15min chart shows Bollinger Bands Expanding Downward, KDJ Death Cross.

Quantum BioPharma's 15-minute chart has triggered a Bollinger Bands Expanding Downward pattern, accompanied by a KDJ Death Cross at 09/11/2025 11:45. This indicates that the market trend is currently being driven by sellers, and the momentum of the stock price is shifting towards the downside, suggesting a potential for further decreases.

Quantum BioPharma Ltd. (NASDAQ: QNTM), a biopharmaceutical company focused on treating challenging neurodegenerative and metabolic disorders, has seen its stock price face bearish indicators, according to technical analysis. On September 11, 2025, at 11:45 AM, the 15-minute chart of Quantum BioPharma triggered a Bollinger Bands Expanding Downward pattern, accompanied by a KDJ Death Cross. These indicators suggest that the market trend is currently driven by sellers, and the momentum of the stock price is shifting towards the downside, potentially signaling further decreases Kingswood Capital Partners Initiates Analyst Coverage on Quantum BioPharma with a BUY Rating and US$45 Price Target^[1].

This comes as Kingswood Capital Partners has initiated coverage of Quantum BioPharma with a BUY rating and a discounted cash flow-based US $45 price target, assuming successful Phase 2 and 3 trials of Lucid-MS in the 2026-2028 timeframe and a commercial launch in 2029 . The lead analyst, Karen Sterling, PhD, CFA, Senior Equity Analyst at Kingswood Capital Partners, has provided this coverage unpaid and without any consideration from Quantum BioPharma.

Quantum BioPharma is dedicated to building a portfolio of innovative assets and biotech solutions, with its lead compound, Lucid-MS, showing promise in preventing and reversing myelin degradation, the underlying mechanism of multiple sclerosis. The company's wholly owned subsidiary, Lucid Psycheceuticals Inc., is focused on the research and development of Lucid-MS. Additionally, Quantum BioPharma retains ownership of 20.10% of Unbuzzd Wellness Inc., a company spun out from Quantum BioPharma's OTC version of unbuzzd™, with royalty payments of 7% of sales from unbuzzd™ until payments to Quantum BioPharma total $250 million .

Kingswood Capital Partners U.S. is a leading wealth management platform with over $20 billion in client assets under management, providing comprehensive financial planning and investment advisory services. With a commitment to independence and client-first advice, Kingswood empowers its advisors to deliver tailored wealth management strategies while offering clients access to global markets and institutional-quality solutions .

Quantum BioPharma's forward-looking statements, as outlined in its press release, contain risks and uncertainties that may cause actual results to differ materially from those expressed. Investors are urged to refer to additional information relating to Quantum BioPharma, including its annual information form, which can be located on the SEDAR+ website at www.sedarplus.ca and on the EDGAR section of the United States Securities and Exchange Commission’s website at www.sec.gov for a more complete discussion of such risk factors and their potential effects .